Anti-obesity Medication Market Size, Share & Trends Analysis Report By Product (Approved, Off Label), By Mechanism of Action (Peripherally Acting Drugs, Centrally Acting Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: March 09, 2026 | Author: Mitiksha Koul | Format: | Report Code: SR5874DR | Pages: 160

Market Segmentation

  1. Anti-obesity Medication Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Approved
      1. Bupropion-naltrexone (Contrave)
      2. Liraglutide (Orlistat)
      3. Orlistat
        1. Xenical
        2. Alli
      4. Phentermine-topiramate (Qsymia)
      5. Semaglutide (Wegovy)
      6. Setmelanotide (Imcivree)
      7. Tirzepatide (Zepbound)
    2. Off Label
      1. Semaglutide (Xenical Alli)
      2. Liraglutide (Semaglutide (Wegovy))
      3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
      4. Others
  2. Anti-obesity Medication Market, By Mechanism of Action 2022-2034 (USD MILLION/ Units)
    1. Peripherally Acting Drugs
    2. Centrally Acting Drugs
  3. Anti-obesity Medication Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Retail Pharmacies
    2. Hospital Pharmacies
    3. Others
  4. Regional Anti-obesity Medication Market
    1. North America
      1. North America Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. North America Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. North America Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. U.S.
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      5. Canada
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
    2. Europe
      1. Europe Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. Europe Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. Europe Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. U.K.
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      5. Germany
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      6. France
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      7. Spain
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      8. Italy
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      9. Russia
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      10. Nordic
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      11. Benelux
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      12. Rest of Europe
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
    3. APAC
      1. APAC Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. APAC Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. APAC Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. China
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      5. Korea
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      6. Japan
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      7. India
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      8. Australia
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      9. Singapore
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      10. Taiwan
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      11. South East Asia
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      12. Rest of Asia-Pacific
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
    4. Middle East and Africa
      1. Middle East and Africa Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. Middle East and Africa Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. Middle East and Africa Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. UAE
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      5. Turkey
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      6. Saudi Arabia
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      7. South Africa
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      8. Egypt
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      9. Nigeria
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      10. Rest of MEA
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
    5. LATAM
      1. LATAM Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. LATAM Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. LATAM Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. Brazil
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      5. Mexico
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      6. Argentina
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      7. Chile
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      8. Colombia
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      9. Rest of LATAM
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on: